Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast for Mucociliary Clearance in COPD
NCT03073798Phase 4Completed
- Sponsor
- Johns Hopkins University
- Start
- Mar 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of roflumilast in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) (2 arms), sponsored by Johns Hopkins University. Primary endpoints: Mucociliary Clearance (0-30 minutes), Mucociliary Clearance (0-60 minutes) and 2 more. Started Mar 2013; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on NCT03073798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03073798.